PTC Therapeutics, Inc. (PTCT) stock
Close on Nov 11, 2026Market cap $5.42BP/E –Yield –
PTC Therapeutics, Inc. saw revenue fall 35.1% to $1.16B over the twelve months to Sep 30, 2026. Operating income fell 81.0% to $147.70M, moving the operating margin from 43.6% to 12.8%. Free cash flow was $2.07M, down 99.7% from a year earlier. At the latest close the market valued the company at $5.42B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $5.42B
- P/E ratio
- –
- Price to sales
- 4.69
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 0.04%
Fundamentals
- Revenue
- $1.16B
- Net income
- -$105.97M
- EPS, diluted
- -$1.19
- Free cash flow
- $2.07M
- Book value per share
- -$2.29
- Diluted shares
- 83M
Trading
- Next earnings
- Jan 11, 2027 (estimated, during market hours)
- Previous close
- $64.14
- Open
- $64.03
- Day's range
- $63.62 – $65.04
- Volume
- 724,937
- Average volume (20 days)
- 1,116,186
- Index membership
- S&P SmallCap 600 (since Nov 2025), Russell 2000, Russell 3000
- Beta (5 years)
- 1.10
- 52-week range
- $58.80 – $90.87
- RSI (14 days)
- 52.0
- Volatility (1 year)
- 42.9%
- Relative volume
- 0.63×
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTCT | S&P 500 | Difference | PTCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.3% | -2.4% | +2.7 pts | ||
| 3 months | -11.9% | -1.2% | −10.8 pts | ||
| Year to date | -14.5% | +12.3% | −26.8 pts | ||
| 1 year | -12.1% | +12.4% | −24.5 pts | ||
| 3 years | +250.1% | +78.8% | +171.3 pts | +51.8% | +21.4% |
| 5 years | +63.5% | +75.2% | −11.7 pts | +10.3% | +11.9% |
| 10 years | +474.4% | +311.1% | +163.3 pts | +19.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PTC Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Results
About PTC Therapeutics
Pharmaceutical Preparations
PTC Therapeutics is a global biopharmaceutical enterprise focused on discovering, developing, and commercializing therapies for children and adults living with rare disorders. Its operations center on treatments for neurological and metabolic conditions, featuring a commercial portfolio that includes Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza and Kebilidi for AADC deficiency. It also commercializes Tegsedi and Waylivra in specific regions and partners on Evrysdi for spinal muscular atrophy. The company serves pediatric and adult patients who have unmet medical needs.
Company profile, executives and historyPTC Therapeutics stock: common questions
What is PTC Therapeutics's stock price?
PTCT closed at $64.91 on Nov 11, 2026, up 1.20% on the day. Over the past 52 weeks it traded between $58.80 and $90.87.
What is PTC Therapeutics's market cap?
PTC Therapeutics was worth $5.42B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PTCT's P/E ratio?
PTC Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.19), so it has no meaningful P/E ratio.
How much revenue does PTC Therapeutics make?
PTC Therapeutics reported revenue of $1.16B for the twelve months to Sep 30, 2026, down 35.1% from a year earlier.
Does PTC Therapeutics pay a dividend?
No. PTC Therapeutics has not paid a cash dividend over the last twelve months.
When does PTC Therapeutics report earnings next?
PTC Therapeutics is expected to report Q4 FY2026 results on Jan 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PTCT stock performed over the past year?
Including dividends, PTCT returned -12.1% over the past year, against +12.4% for the S&P 500.
How many PTCT shares are sold short?
8M shares were sold short at the latest FINRA report, 9.60% of the float, or 7.5 days of average trading volume.
Who are PTC Therapeutics's competitors?
Companies most similar to PTC Therapeutics by business, industry and size include IONS, INSM, ACAD, SRPT, MIRM.
See a number that looks wrong?